The U.S. government has approved a research study in which Geron, a California biotech company, will use experimental therapies to treat patients with severe spinal cord injuries, the Washington Post reported Saturday.

The company will use cells from leftover embryos at fertility clinics derived before former President George W. Bush prohibited federal funding of such research.  Advocates in the field see the Geron approval as a mere first step in more embryonic stem cell, anticipating that President Obama will lift the funding prohibition.

Given mounting successes in the use of adult stem cells, I found interesting a quote from the Post article:

Robert Lanza of Advanced Cell Technology in Worcester, Mass., which plans to ask the FDA to approve a study using embryonic stem cells to treat blindness. “The field desperately needs a big clinical success. It’s very important to show the naysayers that this is very real, and hopefully it will start helping people.”

Shouldn’t a “big clinical success” precede the notion that the medical efficacy of embryonic stem cells is “very real”?